Diabetes & Metabolism Journal

Original Articles

Agreement between Framingham Risk Score and United Kingdom Prospective Diabetes Study Risk Engine in Identifying High Coronary Heart Disease Risk in North Indian Population: Dipika Bansal, Ramya S. R. Nayakallu, Kapil Gudala, Rajavikram Vyamasuni, Anil Bhansali; Diabetes Metab J. 2015;39(4):321-327. Published online July 8, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.4.321

2,961 View
30 Download
11 Web of Science
12 Crossref

Background

The aim of the study is to evaluate the concurrence between Framingham Risk score (FRS) and United Kingdom Prospective Diabetes Study (UKPDS) risk engine in identifying coronary heart disease (CHD) risk in newly detected diabetes mellitus patients and to explore the characteristics associated with the discrepancy between them.

Methods

A cross-sectional study involving 489 subjects newly diagnosed with type 2 diabetes mellitus was conducted. Agreement between FRS and UKPDS in classifying patients as high risk was calculated using kappa statistic. Subjects with discrepant scores between two algorithms were identified and associated variables were determined.

Results

The FRS identified 20.9% subjects (range, 17.5 to 24.7) as high-risk while UKPDS identified 21.75% (range, 18.3 to 25.5) as high-risk. Discrepancy was observed in 17.9% (range, 14.7 to 21.7) subjects. About 9.4% had high risk by UKPDS but not FRS, and 8.6% had high risk by FRS but not UKPDS. The best agreement was observed at high-risk threshold of 20% for both (κ=0.463). Analysis showed that subjects having high risk on FRS but not UKPDS were elderly females having raised systolic and diastolic blood pressure. Patients with high risk on UKPDS but not FRS were males and have high glycosylated hemoglobin.

Conclusion

The FRS and UKPDS (threshold 20%) identified different populations as being at high risk, though the agreement between them was fairly good. The concurrence of a number of factors (e.g., male sex, low high density lipoprotein cholesterol, and smoking) in both algorithms should be regarded as increasing the CHD risk. However, longitudinal follow-up is required to form firm conclusions.

Citations

Citations to this article as recorded by

Endocan is Related to Increased Cardiovascular Risk in Type 2 Diabetes Mellitus Patients
Aleksandra Klisic, Jelena Kotur-Stevuljevic, Ana Ninic
Metabolic Syndrome and Related Disorders.2023; 21(7): 362. CrossRef
Estimated risk of cardiovascular events and long-term complications: The projected future of diabetes patients in Delhi from the DEDICOM-II survey
Swapnil Rawat, Ramasheesh Yadav, Siddhi Goyal, Jitender Nagpal
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(11): 102880. CrossRef
Cardiovascular Biomarkers and Calculated Cardiovascular Risk in Orally Treated Type 2 Diabetes Patients: Is There a Link?
Aleksandra Markova, Mihail Boyanov, Deniz Bakalov, Atanas Kundurdjiev, Adelina Tsakova
Hormone and Metabolic Research.2021; 53(01): 41. CrossRef
Risk of coronary heart disease and stroke based on United Kingdom prospective diabetes study in type 2 DM patients in Medan
R Amelia, J Harahap, H Wijaya, I I Fujiati
IOP Conference Series: Earth and Environmental Science.2021; 912(1): 012081. CrossRef
Cardiovascular/stroke risk prevention: A new machine learning framework integrating carotid ultrasound image-based phenotypes and its harmonics with conventional risk factors
Ankush Jamthikar, Deep Gupta, Narendra N. Khanna, Luca Saba, John R. Laird, Jasjit S. Suri
Indian Heart Journal.2020; 72(4): 258. CrossRef
Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors
Cosmin Mihai Vesa, Loredana Popa, Amorin Remus Popa, Marius Rus, Andreea Atena Zaha, Simona Bungau, Delia Mirela Tit, Raluca Anca Corb Aron, Dana Carmen Zaha
Diagnostics.2020; 10(5): 314. CrossRef
Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound
Ankush D. Jamthikar, Deep Gupta, Luca Saba, Narendra N. Khanna, Klaudija Viskovic, Sophie Mavrogeni, John R. Laird, Naveed Sattar, Amer M. Johri, Gyan Pareek, Martin Miner, Petros P. Sfikakis, Athanasios Protogerou, Vijay Viswanathan, Aditya Sharma, Georg
Computers in Biology and Medicine.2020; 126: 104043. CrossRef
Additive and Synergistic Cardiovascular Disease Risk Factors and HIV Disease Markers' Effects on White Matter Microstructure in Virally Suppressed HIV
Maëliss Calon, Kritika Menon, Andrew Carr, Roland G. Henry, Caroline D. Rae, Bruce J. Brew, Lucette A. Cysique
JAIDS Journal of Acquired Immune Deficiency Syndromes.2020; 84(5): 543. CrossRef
Performance evaluation of 10-year ultrasound image-based stroke/cardiovascular (CV) risk calculator by comparing against ten conventional CV risk calculators: A diabetic study
Narendra N. Khanna, Ankush D. Jamthikar, Deep Gupta, Andrew Nicolaides, Tadashi Araki, Luca Saba, Elisa Cuadrado-Godia, Aditya Sharma, Tomaz Omerzu, Harman S. Suri, Ajay Gupta, Sophie Mavrogeni, Monika Turk, John R. Laird, Athanasios Protogerou, Petros P.
Computers in Biology and Medicine.2019; 105: 125. CrossRef
Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes
Nebojsa Kavaric, Aleksandra Klisic, Ana Ninic
Open Medicine.2018; 13(1): 610. CrossRef
Differential Association of Metabolic Risk Factors with Open Angle Glaucoma according to Obesity in a Korean Population
Hyun-Ah Kim, Kyungdo Han, Yun-Ah Lee, Jin A Choi, Yong-Moon Park
Scientific Reports.2016;[Epub] CrossRef
The Association between Diabetic Retinopathy and Framingham Risk Score in Koreans with Type II Diabetes
Da Yeong Kim, Su Jeong Song, Jeong Hun Bae, Cheol-Young Park, Eun-Jung Rhee
Journal of the Korean Ophthalmological Society.2016; 57(5): 779. CrossRef

Ruboxistaurin for the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review of Randomized Clinical Trials: Dipika Bansal, Yogesh Badhan, Kapil Gudala, Fabrizio Schifano; Diabetes Metab J. 2013;37(5):375-384. Published online October 17, 2013; DOI: https://doi.org/10.4093/dmj.2013.37.5.375

4,770 View
65 Download
51 Crossref

Abstract PDF PubReader

Background

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus. Protein kinase C (PKC) inhibitor's has been thought to be a potential disease modifying drug's in DPN as it slows or reverse neuropathy's progression. To assesses the efficacy and safety of ruboxistaurin on the progression of symptoms, signs, or functional disability in DPN.

Methods

A systematic review of the literature databases like PubMed, ProQuest, EBSCO, EMBASE, and Cochrane Central was performed up to August 2012. We included randomized controlled trials (RCTs) comparing PKC inhibitor ruboxistaurin (RBX) with control and lasting at least 6 months. Our primary outcome measure was change in neurological examination, measured by neurological total symptom score (NTSS) and vibration detection threshold (VDT). Secondary outcome measures were total quality of life (QoL), skin microvascular blood flow and others.

Results

Six RCTs were included in review. Change in neurological function assessed by NTSS was reported in six studies, out of which significant difference between the RBX and placebo group seen in four studies favouring treatment group while remaining two studies reported no significant difference. VDT was assessed in only one study in which no significant difference seen between RBX and placebo group. Two studies reported significant improvement in QoL data. Safety data was reported in only two studies in which none of side effect was related to RBX.

Conclusion

RBX had effects on DPN in some studies, but the evidence is not enough for meta-analysis and firm conclusion.

Citations

Citations to this article as recorded by

Painful Diabetic Neuropathy: The Need for New Approaches
Andrea M. Yeung, Jingtong Huang, Kevin T. Nguyen, Nicole Y. Xu, Lorenzo T. Hughes, Brajesh K. Agrawal, Niels Ejskjaer, David C. Klonoff
Journal of Diabetes Science and Technology.2024; 18(1): 159. CrossRef
Cell metabolism pathways involved in the pathophysiological changes of diabetic peripheral neuropathy
Yaowei Lv, Xiangyun Yao, Xiao Li, Yuanming Ouyang, Cunyi Fan, Yun Qian
Neural Regeneration Research.2024; 19(3): 598. CrossRef
Diabetic sensory neuropathy and insulin resistance are induced by loss of UCHL1 in Drosophila
Daewon Lee, Eunju Yoon, Su Jin Ham, Kunwoo Lee, Hansaem Jang, Daihn Woo, Da Hyun Lee, Sehyeon Kim, Sekyu Choi, Jongkyeong Chung
Nature Communications.2024;[Epub] CrossRef
Non-Muscle Myosin IIC as a Prognostic and Therapeutic Target in Cancer
Ghulam Jilany Khan, Sajal Salman, Zhu Chen, Song Li, Hui Chen, Yan Deng, Nongyue He
Journal of Biomedical Nanotechnology.2024; 20(3): 438. CrossRef
New Horizons in Diabetic Neuropathies: An Updated Review on their Pathology, Diagnosis, Mechanism, Screening Techniques, Pharmacological, and Future Approaches
Namra Aziz, Biswajit Dash, Pranay Wal, Prachi Kumari, Poonam Joshi, Ankita wal
Current Diabetes Reviews.2024;[Epub] CrossRef
Nanoformulations of flavonoids for diabetes and microvascular diabetic complications
Kopal Agarawal, Yogesh Anant Kulkarni, Sarika Wairkar
Drug Delivery and Translational Research.2023; 13(1): 18. CrossRef
Determination of Ruboxistaurin analysis in rat plasma utilizing LC–MS/MS technique
Bushra T. AlQuadeib, Fadilah S. Aleanizy, Fulwah Y. Alqahtani, Rehab A. Alshammari, Amal Aldarwesh, Ibrahim Alsarra
Saudi Pharmaceutical Journal.2023; 31(4): 547. CrossRef
New perspectives in diabetic neuropathy
Stephanie A. Eid, Amy E. Rumora, Bogdan Beirowski, David L. Bennett, Junguk Hur, Masha G. Savelieff, Eva L. Feldman
Neuron.2023; 111(17): 2623. CrossRef
Issues and challenges in diabetic neuropathy management: A narrative review
Che Aishah Nazariah Ismail
World Journal of Diabetes.2023; 14(6): 741. CrossRef
Plasma Metabolomics and Lipidomics Differentiate Obese Individuals by Peripheral Neuropathy Status
Kai Guo, Masha G Savelieff, Amy E Rumora, Fadhl M Alakwaa, Brian C Callaghan, Junguk Hur, Eva L Feldman
The Journal of Clinical Endocrinology & Metabolism.2022; 107(4): 1091. CrossRef
The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy
Seyed Hossein Aghamiri, Khalil Komlakh, Mehran Ghaffari
Inflammopharmacology.2022; 30(1): 51. CrossRef
10.6-μm infrared laser as adjuvant therapy for diabetic peripheral neuropathy: study protocol for a double-blind, randomized controlled trial
Lin Lin, Yi Chen, Yuxia Li, Ke Cheng, Haiping Deng, Jianping Lu, Ling Zhao, Xueyong Shen
Trials.2022;[Epub] CrossRef
Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?
Dalal Y. Al-Bazz, Andrew J. Nelson, Jamie Burgess, Ioannis N. Petropoulos, Jael Nizza, Anne Marshall, Emily Brown, Daniel J. Cuthbertson, Andrew G. Marshall, Rayaz A. Malik, Uazman Alam
Diagnostics.2022; 12(3): 731. CrossRef
Prospective dietary radical scavengers: Boon in Pharmacokinetics, overcome insulin obstruction via signaling cascade for absorption during impediments in metabolic disorder like Diabetic Mellitus
Varuna Suresh, John Kunnath, Amala Reddy
Journal of Diabetes & Metabolic Disorders.2022; 21(1): 1149. CrossRef
The Treatment of Painful Diabetic Neuropathy
Gordon Sloan, Uazman Alam, Dinesh Selvarajah, Solomon Tesfaye
Current Diabetes Reviews.2022;[Epub] CrossRef
Effect of Cognitive-Behavioral Therapy or Mindfulness Therapy on Pain and Quality of Life in Patients with Diabetic Neuropathy: A Systematic Review and Meta-Analysis
Yuan Bai, Jun-Hong Ma, Ying Yu, Zhi-Wen Wang
Pain Management Nursing.2022; 23(6): 861. CrossRef
Emerging drugs for the treatment of diabetic nephropathy
Yoon Kook Kim, Xinyuan Ning, Kashif M. Munir, Stephen N. Davis
Expert Opinion on Emerging Drugs.2022; 27(4): 417. CrossRef
Novel treatment modalities for painful diabetic neuropathy
A. Rastogi, E.B. Jude
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 287. CrossRef
Effectiveness and safety of low-level laser therapy in diabetic peripheral neuropathy: a protocol for a systematic review and meta-analysis
Lin Lin, Jingjing Li, Jingshan Lin, Shiheng Tang, Yuxia Li
Systematic Reviews.2021;[Epub] CrossRef
Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes
Amy E. Rumora, Kai Guo, Fadhl M. Alakwaa, Signe T. Andersen, Evan L. Reynolds, Marit E. Jørgensen, Daniel R. Witte, Hatice Tankisi, Morten Charles, Masha G. Savelieff, Brian C. Callaghan, Troels S. Jensen, Eva L. Feldman
Annals of Clinical and Translational Neurology.2021; 8(6): 1292. CrossRef
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Gordon Sloan, Dinesh Selvarajah, Solomon Tesfaye
Nature Reviews Endocrinology.2021; 17(7): 400. CrossRef
Diabetic neuropathy: an insight on the transition from synthetic drugs to herbal therapies
Komal Arora, Pushpa C. Tomar, Vandana Mohan
Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1773. CrossRef
Synthesis and Antiplasmodial Activity of Bisindolylcyclobutenediones
Duc Hoàng Lande, Abed Nasereddin, Arne Alder, Tim W. Gilberger, Ron Dzikowski, Johann Grünefeld, Conrad Kunick
Molecules.2021; 26(16): 4739. CrossRef
High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy
Chialin Cheng, Surya A. Reis, Emily T. Adams, Daniel M. Fass, Steven P. Angus, Timothy J. Stuhlmiller, Jared Richardson, Hailey Olafson, Eric T. Wang, Debasis Patnaik, Roberta L. Beauchamp, Danielle A. Feldman, M. Catarina Silva, Mriganka Sur, Gary L. Joh
Scientific Reports.2021;[Epub] CrossRef
Management of diabetic neuropathy
Simona Cernea, Itamar Raz
Metabolism.2021; 123: 154867. CrossRef
29th Annual GP2A Medicinal Chemistry Conference
Jean-Jacques Helesbeux, Laura Carro, Florence O. McCarthy, Vânia M. Moreira, Francesca Giuntini, Niamh O’Boyle, Susan E. Matthews, Gülşah Bayraktar, Samuel Bertrand, Christophe Rochais, Pascal Marchand
Pharmaceuticals.2021; 14(12): 1278. CrossRef
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Lei Pang, Xin Lian, Huanqiu Liu, Yuan Zhang, Qian Li, Yin Cai, Haichun Ma, Xin Yu
Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef
Treatment of Diabetic Cardiovascular Autonomic, Peripheral and Painful Neuropathy. Focus on the Treatment of Cardiovascular Autonomic Neuropathy with ACE Inhibitors
Triantafyllos Didangelos, Aristidis Veves
Current Vascular Pharmacology.2020; 18(2): 158. CrossRef
Mechanisms of small nerve fiber pathology
Franziska Gross, Nurcan Üçeyler
Neuroscience Letters.2020; 737: 135316. CrossRef
Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants associated with Diabetic Nephropathy
Jing Guo, Owen J. L. Rackham, Niina Sandholm, Bing He, Anne-May Österholm, Erkka Valo, Valma Harjutsalo, Carol Forsblom, Iiro Toppila, Maija Parkkonen, Qibin Li, Wenjuan Zhu, Nathan Harmston, Sonia Chothani, Miina K. Öhman, Eudora Eng, Yang Sun, Enrico Pe
Journal of the American Society of Nephrology.2020; 31(2): 309. CrossRef
SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice
Xialin Zhu, Yun Chen, Xu Xu, Xiaoju Xu, Yin Lu, Xi Huang, Jinpei Zhou, Lihong Hu, Jiaying Wang, Xu Shen
EBioMedicine.2020; 61: 103061. CrossRef
Targeting Mitochondrial Fission-Fusion Imbalance in Heart Failure
Thiago N. Menezes, Lisley S. Ramalho, Luiz R. G. Bechara, Julio Cesar Batista Ferreira
Current Tissue Microenvironment Reports.2020; 1(4): 239. CrossRef
Recent advances in the pathogenesis of microvascular complications in diabetes
Sungmi Park, Hyeon-Ji Kang, Jae-Han Jeon, Min-Ji Kim, In-Kyu Lee
Archives of Pharmacal Research.2019; 42(3): 252. CrossRef
Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Neeraj Kumar, Anita Singh, Dinesh Kumar Sharma, Kamal Kishore
Current Signal Transduction Therapy.2019; 14(2): 107. CrossRef
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Saikat Dewanjee, Sonjit Das, Anup Kumar Das, Niloy Bhattacharjee, Anjum Dihingia, Tarun K. Dua, Jatin Kalita, Prasenjit Manna
European Journal of Pharmacology.2018; 833: 472. CrossRef
Interventions for Neuropathic Pain: An Overview of Systematic Reviews
Svjetlana Dosenovic, Antonia Jelicic Kadic, Maja Miljanovic, Marina Biocic, Krste Boric, Marija Cavar, Nikolina Markovina, Katarina Vucic, Livia Puljak
Anesthesia & Analgesia.2017; 125(2): 643. CrossRef
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Eva L. Feldman, Klaus-Armin Nave, Troels S. Jensen, David L.H. Bennett
Neuron.2017; 93(6): 1296. CrossRef
Rutin suppresses high glucose-induced ACTA2 and p38 protein expression in diabetic nephropathy
Chun-Shan Han, Kai Liu, Ning Zhang, Shi-Wen Li, Hai-Cheng Gao
Experimental and Therapeutic Medicine.2017; 14(1): 181. CrossRef
Protein kinase C participation in the mechanisms of vascular tone disturbance upon diabetes mellitus. Part 4
I. Kizub, O. Kharchenko, O. Kostiuk, L. Ostapchenko, K. Klymenko, A. Soloviev
Bulletin of Taras Shevchenko National University of Kyiv. Series: Problems of Physiological Functions Regulation.2016; 21(2): 61. CrossRef
Emerging drugs for diabetic peripheral neuropathy and neuropathic pain
Nikolaos Papanas, Dan Ziegler
Expert Opinion on Emerging Drugs.2016; 21(4): 393. CrossRef
Pancreatic β Cell Mass Death
Husnia I. Marrif, Salma I. Al-Sunousi
Frontiers in Pharmacology.2016;[Epub] CrossRef
Efficacy and safety of prostaglandin E1 plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral neuropathy
De-Qi Jiang, Ming-Xing Li, Yan-Jiao Ma, Yan Wang, Yong Wang
Journal of Clinical Neuroscience.2016; 27: 8. CrossRef
Nonbiological pharmacotherapies for the treatment of diabetic macular edema
Aniruddha Agarwal, Jacob Parriott, Sibel Demirel, Colby Argo, Yasir Jamal Sepah, Diana V Do, Quan Dong Nguyen
Expert Opinion on Pharmacotherapy.2015; 16(17): 2625. CrossRef
Present and Future in the Treatment of Diabetic Kidney Disease
Borja Quiroga, David Arroyo, Gabriel de Arriba
Journal of Diabetes Research.2015; 2015: 1. CrossRef
Choosing drugs for the treatment of diabetic neuropathy
Majed Alabdali, Mohammad Qrimli, Carolina Barnett, Alon Abraham, Ari Breiner, Hans D Katzberg, Danah Aljaafari, Hana Albulaihe, Bruce A Perkins, Vera Bril
Expert Opinion on Pharmacotherapy.2015; 16(12): 1805. CrossRef
Burning through the pain: treatments for diabetic neuropathy
S. Javed, U. Alam, R. A. Malik
Diabetes, Obesity and Metabolism.2015; 17(12): 1115. CrossRef
Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220
Abdullah Mayati, Arnaud Bruyere, Amélie Moreau, Elodie Jouan, Claire Denizot, Yannick Parmentier, Olivier Fardel, Jeff M Sands
PLOS ONE.2015; 10(12): e0144667. CrossRef
Targeting caveolin-3 for the treatment of diabetic cardiomyopathy
Lucy Murfitt, Gareth Whiteley, Mohammad M. Iqbal, Ashraf Kitmitto
Pharmacology & Therapeutics.2015; 151: 50. CrossRef
Protein kinase C in enhanced vascular tone in diabetes mellitus
Igor V. Kizub, Kateryna I. Klymenko, Anatoly I. Soloviev
International Journal of Cardiology.2014; 174(2): 230. CrossRef
Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy
Houliang Deng, JinJin Yin, JingJing Zhang, Qian Xu, Xiaoxia Liu, Li Liu, Zhuomin Wu, Aimin Ji
Endocrine.2014; 46(3): 445. CrossRef
Efficacy of α-lipoic acid in diabetic neuropathy
Nikolaos Papanas, Dan Ziegler
Expert Opinion on Pharmacotherapy.2014; 15(18): 2721. CrossRef

First
Prev
Page of 1
Next
Last

Search